[go: up one dir, main page]

WO2009022354A3 - Formes pharmaceutiques modifiées de tacrolimus - Google Patents

Formes pharmaceutiques modifiées de tacrolimus Download PDF

Info

Publication number
WO2009022354A3
WO2009022354A3 PCT/IN2008/000179 IN2008000179W WO2009022354A3 WO 2009022354 A3 WO2009022354 A3 WO 2009022354A3 IN 2008000179 W IN2008000179 W IN 2008000179W WO 2009022354 A3 WO2009022354 A3 WO 2009022354A3
Authority
WO
WIPO (PCT)
Prior art keywords
tacrolimus
amount
hours
released
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2008/000179
Other languages
English (en)
Other versions
WO2009022354A2 (fr
Inventor
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Rajesh Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39642954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009022354(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/530,011 priority Critical patent/US20100086592A1/en
Priority to AU2008288105A priority patent/AU2008288105A1/en
Priority to CA002680680A priority patent/CA2680680A1/fr
Priority to MX2009010556A priority patent/MX2009010556A/es
Priority to NZ579811A priority patent/NZ579811A/en
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Priority to EA200970897A priority patent/EA200970897A1/ru
Priority to BRPI0809563-9A2A priority patent/BRPI0809563A2/pt
Priority to JP2010500442A priority patent/JP2010522742A/ja
Publication of WO2009022354A2 publication Critical patent/WO2009022354A2/fr
Publication of WO2009022354A3 publication Critical patent/WO2009022354A3/fr
Priority to IL201008A priority patent/IL201008A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme pharmaceutique à libération modifiée de tacrolimus qui libère deux ou des quantités de tacrolimus lors de l'administration orale. La première quantité de tacrolimus est libérée à partir de l'unité pharmaceutique à libération immédiate quasiment immédiatement dans les 0 à 2 heures suivie par un intervalle de temps s'étendant d'environ 1 à 10 heures durant lequel quasiment aucune quantité de tacrolimus n'est libérée à partir de la forme pharmaceutique, après laquelle une seconde quantité de tacrolimus est libérée, ladite seconde quantité étant libérée à partir de l'unité pharmaceutique à libération différée, soit immédiatement, par exemple dans les 0 à 2 heures, soit sur une période de temps s'étendant d'environ 2 à 12 heures suivant sa libération initiale à partir de l'unité pharmaceutique à dosage différé. La forme pharmaceutique peut en outre comprendre une quantité additionnelle de tacrolimus afin de fournir une impulsion additionnelle de tacrolimus. Les formes pharmaceutiques de tacrolimus présentent une biodisponibilité améliorée et un flux ou des fluctuations réduits par rapport à la composition existante de tacrolimus. L'invention concerne également un procédé de préparation des formes pharmaceutiques.
PCT/IN2008/000179 2007-03-29 2008-03-25 Formes pharmaceutiques modifiées de tacrolimus Ceased WO2009022354A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2010500442A JP2010522742A (ja) 2007-03-29 2008-03-25 タクロリムスの修飾型剤形
BRPI0809563-9A2A BRPI0809563A2 (pt) 2007-03-29 2008-03-25 Formas de dosagem modificadas de tacrolimus
CA002680680A CA2680680A1 (fr) 2007-03-29 2008-03-25 Formes pharmaceutiques modifiees de tacrolimus
MX2009010556A MX2009010556A (es) 2007-03-29 2008-03-25 Formas de dosificacion modificada de tacrolimus.
NZ579811A NZ579811A (en) 2007-03-29 2008-03-25 Modified dosage forms of tacrolimus
US12/530,011 US20100086592A1 (en) 2007-03-29 2008-03-25 Modified dosage forms of tacrolimus
EA200970897A EA200970897A1 (ru) 2007-03-29 2008-03-25 Модифицированные лекарственные формы такролимуса
AU2008288105A AU2008288105A1 (en) 2007-03-29 2008-03-25 Modified dosage forms of tacrolimus
IL201008A IL201008A0 (en) 2007-03-29 2009-09-17 Modified release dosage forms of tacrolimus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN583MU2007 2007-03-29
IN583/MUM/2007 2007-03-29

Publications (2)

Publication Number Publication Date
WO2009022354A2 WO2009022354A2 (fr) 2009-02-19
WO2009022354A3 true WO2009022354A3 (fr) 2009-04-09

Family

ID=39642954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000179 Ceased WO2009022354A2 (fr) 2007-03-29 2008-03-25 Formes pharmaceutiques modifiées de tacrolimus

Country Status (15)

Country Link
US (1) US20100086592A1 (fr)
EP (1) EP1974722A3 (fr)
JP (1) JP2010522742A (fr)
KR (1) KR20100014629A (fr)
CN (1) CN101652141A (fr)
AU (1) AU2008288105A1 (fr)
BR (1) BRPI0809563A2 (fr)
CA (1) CA2680680A1 (fr)
CL (1) CL2008000914A1 (fr)
EA (1) EA200970897A1 (fr)
IL (1) IL201008A0 (fr)
MX (1) MX2009010556A (fr)
NZ (1) NZ579811A (fr)
UA (1) UA93148C2 (fr)
WO (1) WO2009022354A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
EP2167033B1 (fr) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Forme pharmaceutique orale à administrer une fois par jour comportant du tacrolimus
CN102119027A (zh) * 2008-06-26 2011-07-06 麦克内尔-Ppc股份有限公司 含有药物活性剂的包衣颗粒
KR101174183B1 (ko) 2008-11-28 2012-08-16 주식회사 삼양바이오팜 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
CN103068376B (zh) 2010-08-18 2016-04-20 赢创罗姆有限公司 包含一种或多种藻酸盐的抗胃液的药物或营养制剂
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
US8940763B2 (en) 2011-05-10 2015-01-27 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
DE102011053068A1 (de) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Darreichungsform mit stabilisierten Wirkstoffpartikeln
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
CN104507460A (zh) 2012-08-27 2015-04-08 赢创工业集团股份有限公司 抗乙醇影响的抗胃酸药物或保健品组合物
WO2016025533A2 (fr) * 2014-08-11 2016-02-18 Whitehead Institute For Biomedical Research Compositions et méthodes de traitement des synucléinopathies
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
JP2018507209A (ja) 2015-02-20 2018-03-15 サイテック インダストリーズ インコーポレイテッド ジアルキルスルホスクシナート組成物、製造方法、および使用方法
BR112018014661A2 (pt) 2016-01-20 2018-12-11 Theravida Inc composição e composição para uso
UA123785C2 (uk) 2016-03-28 2021-06-02 Інсайт Корпорейшн Сполуки піролотриазину як інгібітори tam
PL3687996T3 (pl) 2017-09-27 2022-02-21 Incyte Corporation Sole pochodnych pirolotriazyny użyteczne jako inhibitory tam
EP4606432A3 (fr) * 2018-06-29 2025-10-29 Incyte Corporation Formulations d'un inhibiteur axl/mer
US20200038560A1 (en) * 2018-07-31 2020-02-06 Cook Medical Technologies Llc Limus coatings and methods of use thereof
CA3063417C (fr) * 2018-12-04 2023-01-03 Leon-Nanodrugs Gmbh Nanoparticules comprenant du tacrolimus
GR1009790B (el) * 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
CN112569187B (zh) * 2019-09-27 2022-04-12 武汉科福新药有限责任公司 一种他克莫司纳米眼用乳及其制备方法
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106248A1 (en) * 2003-11-17 2005-05-19 Manesh Dixit Extended release venlafaxine formulation
WO2005046561A2 (fr) * 2003-11-13 2005-05-26 Röhm GmbH & Co. KG Forme galenique a couches multiples comportant une matrice influant sur la liberation d'une substance a effet modulateur
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100440553B1 (ko) 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SI1663216T1 (sl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Sestavek z modificiranim sproščanjem ki vsebuje takrolimus
WO2005020993A1 (fr) * 2003-08-29 2005-03-10 Lifecycle Pharma A/S Compositions a liberation modifiee, a base de tacrolimus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046561A2 (fr) * 2003-11-13 2005-05-26 Röhm GmbH & Co. KG Forme galenique a couches multiples comportant une matrice influant sur la liberation d'une substance a effet modulateur
US20050106248A1 (en) * 2003-11-17 2005-05-19 Manesh Dixit Extended release venlafaxine formulation
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations

Also Published As

Publication number Publication date
CN101652141A (zh) 2010-02-17
MX2009010556A (es) 2009-10-22
KR20100014629A (ko) 2010-02-10
EP1974722A3 (fr) 2009-03-04
UA93148C2 (ru) 2011-01-10
EP1974722A2 (fr) 2008-10-01
EA200970897A1 (ru) 2010-04-30
BRPI0809563A2 (pt) 2014-09-16
CL2008000914A1 (es) 2008-07-18
NZ579811A (en) 2012-02-24
AU2008288105A1 (en) 2009-02-19
CA2680680A1 (fr) 2009-02-19
US20100086592A1 (en) 2010-04-08
JP2010522742A (ja) 2010-07-08
IL201008A0 (en) 2010-05-17
WO2009022354A2 (fr) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2009022354A3 (fr) Formes pharmaceutiques modifiées de tacrolimus
WO2007090882A3 (fr) Compositions pharmaceutiques
TW200745149A (en) Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2008011126A3 (fr) Compositions liquides d'acétate de calcium
GEP20146166B (en) Pharmaceutical composition
IL194871A (en) Compound linking to bir iap site, intermediate compound, process for compound preparation, method for making acceptable pharmaceutical salt, pharmaceutical preparation and use of compound for drug production
WO2012021629A3 (fr) Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson
WO2009066326A3 (fr) Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables
PL2364983T3 (pl) Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
WO2007001065A3 (fr) Methode pour preparer un produit medicamenteux se presentant sous forme de granules humides
WO2005075425A3 (fr) Derives de bisaryluree
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2011157721A3 (fr) Composition pharmaceutique contenant de l'ivabradine
WO2010138598A3 (fr) Modulateurs des lxr
WO2013012485A3 (fr) Nouvelles formes cristallines de 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)pipéridine-2,6-dione
WO2012052169A3 (fr) Composition pharmaceutique particulaires contenant un opioïde et un antagoniste d'opioïde
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
EA201171271A1 (ru) Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010774.5

Country of ref document: CN

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827263

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2680680

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 201008

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 579811

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2010500442

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008288105

Country of ref document: AU

Ref document number: 1020097020203

Country of ref document: KR

Ref document number: 2009091418

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010556

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008288105

Country of ref document: AU

Date of ref document: 20080325

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09120988

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200970897

Country of ref document: EA

122 Ep: pct application non-entry in european phase

Ref document number: 08827263

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0809563

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090929